Approach to the prostate cancer patient with bone disease

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 1, 2008, Pages 2-7

  Greenspan, Susan L ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM CARBONATE; COLECALCIFEROL; ERGOCALCIFEROL; LEUPRORELIN;

AGED; ANAMNESIS; ANDROGEN THERAPY; BONE DENSITY; BONE DISEASE; CASE REPORT; CLINICAL FEATURE; FOLLOW UP; HUMAN; MALE; OSTEOLYSIS; OSTEOPOROSIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK FACTOR; TREATMENT OUTCOME; VERTEBRA FRACTURE; VITAMIN D DEFICIENCY; X RAY;

EID: 38149080465     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-1402     Document Type: Article

References (49)

1. Seeman E, Bianchi G, Adami S, Kanis J, Khosla S, Orwoll E 2004 Osteoporosis in men-consensus is premature. Calcif Tissue Int 75:120-122
2. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A 2007 Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 22:465-475
3. Seeman E, Bianchi G, Khosla S, Kanis JA, Orwoll E 2006 Bone fragility in men-where are we? Osteoporos Int 17:1577-1583
4. Jiang HX, Majumdar S, Dick DA, Moreau M, Raso J, Otto DD, Johnston DW 2005 Development and initial validation of a risk score for predicting inhospital and 1-year mortality in patients with hip fractures. J Bone Miner Res 20:494-500
5. Looker AC, Orwoll ES, Johnston Jr CC, Lindsay RL, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP 1997 Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res 12:1761-1768
6. Bilezikian JP 1999 Osteoporosis in men. J Clin Endocrinol Metab 84:3431-3434
7. Bonjour JP 1998 Delayed puberty and peak bone mass. Eur J Endocrinol 139:257-259
8. Mora S, Gilsanz V 2003 Establishment of peak bone mass. Endocrinol Metab Clin North Am 32:39-63
9. Beck TJ, Ruff CB, Scott Jr WW, Plato CC, Tobin JD 1992 Sex differences in geometry of the femoral neck with aging: a structural analysis of bone mineral data. Calcif Tissue Int 50:24-29
10. Seeman E 2002 Pathogenesis of bone fragility in women and men. Lancet 359:1841-1850
11. Stock H, Schneider A, Strauss E 2004 Osteoporosis: a disease in men. Clin Orthop 425:143-151
12. Orwoll E, Klein R 1996 Osteoporosis in men. In: Marcus R, Feldman D, Kelsey J, eds. Osteoporosis. San Diego: Academic Press; 745-784
13. Orwoll ES 2006 Osteoporosis in men. In: Favus MJ, ed. Primer on the metabolic bone diseases and disorders of mineral metabolism. Washington, DC: American Society for Bone and Mineral Research; 290-293
14. Kanis JA, Melton III LJ, Christiansen C, Johnston CC, Khaltaev N 1994 The diagnosis of osteoporosis. J Bone Miner Res 9:1137-1141
15. Kanis JA, for the WHO Study Group 1994 Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporos Int 4:368-381
16. Lewiecki EM, Watts NB, McClung MR, Petak SM, Bachrach LK, Shepherd JA, Downs Jr RW, for the International Society for Clinical Densitometry 2004 Official positions of the International Society for Clinical Densitometry. J Clin Endocrinol Metab 89:3651-3655
17. Tannenbaum C, Clark J, Schwartzman K, Wallenstein S, Lapinski R, Meier D, Luckey M 2002 Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab 87:4431-4437
18. Vallarta-Ast N, Krueger D, Wrase C, Agrawal S, Binkley N 2007 Anevaluation of densitometric vertebral fracture assessment in men. Osteoporos Int 18: 1405-1410
19. Lewiecki EM, Laster AJ 2006 Clinical applications of vertebral fracture assessment by dual-energy x-ray absorptiometry. J Clin Endocrinol Metab 91:4215-4222
20. Greenspan SL, von Stetten E, Emond SK, Jones L, Parker RA 2001 Instant vertebral assessment: a noninvasive DXA technique to avoid misclassification and clinical mismanagement of osteoporosis. J Clin Densitom 4:373-380
21. Catalona W 1994 Management of cancer of the prostate. N Engl J Med 331:996-1004
22. Huggins C, Hodges C 1941 Studies in prostate cancer: 1. The effects of castration, of estrogen, and of androgen injection on serum phosphatase in metastatic carcinoma of the prostate. Cancer Res 1:293-297
23. Higano CS 2004 Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician. Urol Clin North Am 31:331-352
24. MRC Prostate Cancer Working Party Investigator's Group 1997 Immediate vs. deferred treatment for advanced prostatic cancer: initial results of the MRC Trial. Brit J Urol 72:235-246
25. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford D, Trump DL 1999 Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341:1781-1788
26. Shahinian VB, Kuo Y-F, Freeman JL, Orihuela E, Goodwin JS 2005 Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 103:1615-1624
27. Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM 2005 Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 90:6410-6417
28. Stoch SA, Parker RA, Chen L, Bubley G, Ko Y-J, Vincelette A, Greenspan SL 2001 Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 86:2787-2791
29. Townsend MF, Sanders WH, Northway RO, Graham SDJ 1997 Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate cancer. Cancer 79:545-550
30. Shahinian VB, Kuo Y-F, Freeman JL, Goodwin JS 2005 Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154-164
31. Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL 2005 Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 23:7897-7903
32. Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, Kantoff PW, Finkelstein JS 2001 Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345:948-955
33. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N 2003 Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169:2008-2012
34. Michaelson MD, Kaufman HL, Lee H, McGovern FJ, Kantoff PW, Fallon MA, Finkelstein JS, Smith MR 2007 Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 25:1038-1042
35. Greenspan SL, Nelson JB, Trump DL, Resnick NM 2007 Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer. A randomized trial. Ann Intern Med 146:416-424
36. Smith MR, Fallon MA, Lee H, Finkelstein JS 2004 Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 89:3841-3846
37. Lewiecki EM 2006 RANK ligand inhibition with denosumab for the management of osteoporosis. Expert Opin Biol Ther 6:1041-1050
38. National Osteoporosis Foundation 2003 Physician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation
39. Holick MF 2007 Vitamin D deficiency. N Engl J Med 357:266-281
40. Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R 2005 Estimates of optimal vitamin D status. Osteoporos Int 16:713-716
41. North American Menopause Society 2006 Management of osteoporosis in postmenopausal women: 2006 position statement of the North American Menopause Society. Menopause 13:340-367
42. Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR 2004 Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy. Cancer 100:899
43. Eastham J 2007 Bone health inmenreceiving androgen deprivation therapy for prostate cancer. J Urol 177:17-24
44. Saad F, Schulman CC 2004 Role of bisphosphonates in prostate cancer. Eur Urol 45:26-34
45. Smith MR 2003 Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma. Cancer 97(3 Suppl):789-795
46. Giovannucci E, Rimm EB, Wolk A 1998 Calcium and fructose intake in relation to risk of prostate cancer. Cancer Res 58:442-447
47. Chan JM, Giovannucci E, Andersson SO, Yuen J, Adami HO, Wolk A 1998 Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer (Sweden). Cancer Causes Control 9:559-566
48. Giovannucci E 1998 Dietary influences of 1,25 (OH)2 vitamin D in relation to prostate cancer: a hypothesis. Cancer Causes Control 9:167-582
49. Cooper C, Atkinson EJ, O'Fallon WM, Melton III LJ 1992 Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res 7:221-227